Valeant Pharmaceuticals International announced that the company has received a request for additional information from the Federal Trade Commission in connection with Valeant's proposed acquisition of Allergan, Inc.
Allergan Inc.'s lawsuit, filed Friday in U.S. District Court in Santa Ana, California, names as...
The Canadian drugmaker now expects 2014 earnings to range between $7.90 and $8.10 per share,...
Pershing Square Capital Management has formally asked Allergan shareholders to support its bid for a special meeting to remove six directors and allow Valeant to proceed with its hostile takeover bid.
Pershing Square, the investment firm run by activist investor Bill Ackman, said Friday it settled a lawsuit with Allergan, the maker of Botox, related to Allergan's poison pill plan and Pershing's $53 billion offer for the company.
Allergan, announced that its Board of Directors, after consultation with its independent financial and legal advisors, unanimously determined that Valeant Pharmaceuticals International, Inc.’s unsolicited exchange offer to acquire all outstanding common shares of Allergan is grossly inadequate.
Akorn has sold its subsidiary, ECR Pharmaceuticals, to Valeant Pharmaceuticals for $41 million in cash and assumption of certain liabilities. ECR, which promotes certain branded pharmaceuticals through its sales force, was acquired through the acquisition of Hi-Tech Pharmacal.
Bill Ackman's Pershing Square Capital Management, seeking legal cover in its $53 billion takeover bid for Allergan, filed a lawsuit to confirm that its push for a special meeting of shareholders won't trigger a defensive "poison pill" plan from the Botox maker.
Valeant Pharmaceuticals aims to take its bid for Allergan to the Botox maker's shareholders after Allegan's board unanimously rejected its latest offer of about $53 billion. Valeant said Tuesday that it looked forward to giving shareholders the opportunity "to speak for themselves" after Allergan Chairman and CEO David Pyott said that the offer wasn't worth discussing in a letter to his Valeant counterpart, Michael Pearson.
Allergan announced that its Board of Directors has unanimously determined that the revised unsolicited proposal from Valeant Pharmaceuticals substantially undervalues the company, creates significant risks and uncertainties for the stockholders of Allergan, and is not in the best interests of the company and its stockholders.
The Food and Drug Administration has approved a toenail fungus treatment from Valeant Pharmaceuticals International Inc. that could reach $800 million in peak U.S. sales, according to the Canadian drugmaker.
Activist investor Bill Ackman said Monday that he will move to replace most of Allergan's board of directors as part of a continuing battle for control of the company.
Valeant Pharmaceuticals is sweetening its offer to buy Botox maker Allergan for the second time this week. The Canadian drugmaker said Friday it is now offering $72 and a portion of its stock for each Allergan share.
Nestle says it is paying $1.4 billion in cash for the rights to sell lip and wrinkle treatment Restylane and other skin products in the U.S. and Canada.
Valeant Pharmaceuticals is adding more cash to its offer to buy Botox maker Allergan in a bid that could now be worth more than $49 billion. The Canadian drugmaker says it will now offer $58.30 and a portion of its stock for each Allergan share.
Valeant Pharmaceuticals International says it will improve its bid of almost $47 billion for Botox-maker Allergan after the company rejected its hostile takeover offer. Valeant CEO Michael Pearson says the company is prepared to pay a fair price, but will remain financially disciplined when it makes its new offer later this month.
Valeant Pharmaceuticals International announced today that certain of its subsidiaries have entered into settlement agreements with affiliates of Actavis plc related to Actavis' generic versions of Acanya Gel, 1.2%/2.5%, and Tiazac XC.
Allergan spurned a takeover bid from Valeant Pharmaceuticals, saying that the unsolicited offer worth nearly $46 billion undervalues the company and carries significant risk.
Valeant says the loss includes restructuring, integration and other charges of $135 million primarily related to the acquisition of eyecare company Bausch + Lomb last year.
Botox maker Allergan raised its outlook for the year Wednesday after topping expectations for the first quarter. Executives did not discuss a $45.6 billion offer last month from Valeant Pharmaceuticals International Inc. and activist investor Bill Ackman to buy the company, but did reiterate that that the proposal is under review.
Valeant Pharmaceuticals International could be pushed to increase the cash component of its bid for Botox maker Allergan by up to 40 per cent, an industry analyst said Monday.
Valeant Pharmaceuticals International says three of its directors will not stand for re-election this year as it pursues the acquisition of Botox maker Allergan, which has adopted a "poison pill" defense while it considers the offer.
WSJ discusses the Ackman/Valeant deal for Allergan.
Drugmakers eager to satisfy shareholders by boosting profits and share prices are wheeling, dealing and in one case even making trades like a pro sports team looking to shake up its roster. The moves could spur more mergers and acquisitions in the industry.
Valeant said Monday that it intends to propose a merger with Allergan using a combination of Valeant stock and cash. The transaction size has not been disclosed, but Valeant expects the cash portion of the deal to be at least $15 billion.
Valeant Pharmaceuticals is seeing more clearly the merits of its acquisition last summer of eye care company Bausch and Lomb and remains on the hunt for another big acquisition this year.
Valeant Pharmaceuticals is looking to expand its skin care business by buying PreCision Dermatology for $475 million. Cumberland, R.I.-based PreCision Dermatology makes treatments for skin ailments such as acne and atopic dermatitis, an itchy, chronic skin inflammation.
Valeant Pharmaceuticals International, Inc. announced today that it has received approval from the Food and Drug Administration (FDA) for its Supplemental New Drug Application (sNDA) for Retin-A Micro (tretinoin) Gel microsphere 0.08% for the topical treatment of acne vulgaris.
- Page 1